GeneDx delivered strong Q1 2025 results, beating revenue and EPS estimates, and raised full-year guidance. The test volume ...

Investigators are using MET immunohistochemistry testing and FDA-approved profiling tools to personalize care and address unmet needs in NSCLC treatment.

Revenues grew to $87.1 million, an increase of 42% year-over-year Exome and genome test revenue grew to $ ... Announced ultraRapid Whole Genome Sequencing, offering accelerated, comprehensive ...

And It Could Help Future Medicine Scientists have just made a fascinating discovery about the roots of the Japanese people.

QGEN inks an agreement to acquire Genoox for $70 million in cash. The acquisition expands QIAGEN's QDI portfolio.

A stunning new genetic study is shaking up everything we thought we knew about Japan’s origins.

Fanconi anemia is an aggressive, life-threatening disorder. Most individuals living with this rare genetic condition ...

The 'heart' of the Fanconi anemia core complex, composed of FANCB-FANCL-FAAP100 (now FANCX) proteins, allows the rest of the ...

and the use of exome sequencing in the DD cohort ahead of the microarray test has not been evaluated. Methods Clinical exome sequencing (CES) was performed on 1090 unrelated Chinese DD patients who ...

Epilepsy in infants is a complex neurological condition that often demands prompt and intensive management. Globally, an ...